• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Multiple Myeloma in a Young Female Presenting with Neurological Symptoms.

作者信息

Lee Matthew, Zhang Xinmin, Nguyen Vinh, Hartley-Brown Monique

机构信息

Internal Medicine Resident, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 300 Community Dr, Manhasset, NY 11030, USA.

Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Pathology Department at North Shore University Hospital-Long Island Jewish Medical Center, 300 Community Dr, Manhasset, NY 11030, USA.

出版信息

Case Rep Hematol. 2020 Feb 13;2020:1375174. doi: 10.1155/2020/1375174. eCollection 2020.

DOI:10.1155/2020/1375174
PMID:32099696
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7040387/
Abstract

BACKGROUND

Multiple myeloma is overall the 14 most common malignancy but is rarely seen in those younger than 35 years. Those in the younger age group have been shown to have a more aggressive course but reportedly have had similar responses to treatment compared to older cohorts. Extramedullary plasmacytomas are discrete soft tissue masses of neoplastic monoclonal plasma cells that often occur in patients with multiple myeloma.

CASE

This case entails a young female with new diagnosis of multiple myeloma and multiple extramedullary plasmacytomas presenting with neurological symptoms. She was treated with CyBorD regimen but was refractory and progressed. Treatment was changed to DCEP regimen, and daratumumab was added for primary refractory myeloma. The patient improved rapidly.

CONCLUSION

This is a unique case of multiple myeloma in a young female that had failed first-line treatment but responded to targeted therapy of daratumumab. It highlights that multiple myeloma may present atypically in young patients. More research is needed on appropriate initial diagnosis and treatment of patients in this age group.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d81/7040387/33b39c8adab3/CRIHEM2020-1375174.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d81/7040387/a449bd089f0e/CRIHEM2020-1375174.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d81/7040387/9b24201f348f/CRIHEM2020-1375174.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d81/7040387/939c12e17e9e/CRIHEM2020-1375174.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d81/7040387/33b39c8adab3/CRIHEM2020-1375174.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d81/7040387/a449bd089f0e/CRIHEM2020-1375174.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d81/7040387/9b24201f348f/CRIHEM2020-1375174.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d81/7040387/939c12e17e9e/CRIHEM2020-1375174.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d81/7040387/33b39c8adab3/CRIHEM2020-1375174.004.jpg

相似文献

1
Multiple Myeloma in a Young Female Presenting with Neurological Symptoms.
Case Rep Hematol. 2020 Feb 13;2020:1375174. doi: 10.1155/2020/1375174. eCollection 2020.
2
Diffuse skeletal muscle extramedullary plasmacytomas: a rare case and review of the literature.弥漫性骨外髓外浆细胞瘤:一例罕见病例并文献复习。
Skeletal Radiol. 2020 Dec;49(12):2087-2093. doi: 10.1007/s00256-020-03514-9. Epub 2020 Jun 19.
3
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience.用于多发性骨髓瘤合并髓外浆细胞瘤或骨旁浆细胞瘤患者的基于达雷妥尤单抗的治疗方案:一项意大利多中心观察性临床经验的初步随访
Ann Hematol. 2024 Dec;103(12):5691-5701. doi: 10.1007/s00277-024-05811-y. Epub 2024 May 28.
4
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.达雷妥尤单抗单药治疗治疗难治性多发性骨髓瘤患者(SIRIUS):一项开放标签、随机、2 期试验。
Lancet. 2016 Apr 9;387(10027):1551-1560. doi: 10.1016/S0140-6736(15)01120-4. Epub 2016 Jan 7.
5
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.达雷妥尤单抗联合泊马度胺和地塞米松与泊马度胺和地塞米松单药治疗既往治疗的多发性骨髓瘤(APOLLO):一项开放标签、随机、III 期临床试验。
Lancet Oncol. 2021 Jun;22(6):801-812. doi: 10.1016/S1470-2045(21)00128-5.
6
DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma.DCEP 联合苯达莫司汀/泼尼松作为四线和五线难治性多发性骨髓瘤的挽救疗法。
Ann Hematol. 2020 May;99(5):1041-1048. doi: 10.1007/s00277-020-03970-2. Epub 2020 Mar 4.
7
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.针对来那度胺和硼替佐米耐药的多发性骨髓瘤患者,CD38 靶向免疫化疗的治疗潜力的临床前证据。
Clin Cancer Res. 2015 Jun 15;21(12):2802-10. doi: 10.1158/1078-0432.CCR-14-1813. Epub 2014 Nov 14.
8
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.皮下注射与静脉注射达雷妥尤单抗治疗复发或难治性多发性骨髓瘤患者(COLUMBA):一项多中心、开放标签、非劣效性、随机、3期试验
Lancet Haematol. 2020 May;7(5):e370-e380. doi: 10.1016/S2352-3026(20)30070-3. Epub 2020 Mar 23.
9
Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis.达雷妥尤单抗耐药在晚期多发性骨髓瘤患者中很常见,与 CD38 表达无关,与预后不良有关。
Eur J Haematol. 2018 May;100(5):494-501. doi: 10.1111/ejh.13046. Epub 2018 Mar 25.
10
Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach.多发性骨髓瘤中的软组织浆细胞瘤:发生率、髓外扩散的机制和治疗方法。
J Clin Oncol. 2011 Oct 1;29(28):3805-12. doi: 10.1200/JCO.2011.34.9290. Epub 2011 Sep 6.

引用本文的文献

1
A Complex Presentation of Multiple Myeloma With Renal Complications in a Young Female: Diagnostic Challenges and Treatment Approach.一名年轻女性多发性骨髓瘤合并肾脏并发症的复杂病例:诊断挑战与治疗方法
EJHaem. 2025 Jan 24;6(1):e1093. doi: 10.1002/jha2.1093. eCollection 2025 Feb.
2
Far and Few Between: Early Onset Multiple Myeloma in a 26-Year-Old Female.罕见病例:一名26岁女性的早发性多发性骨髓瘤
Cureus. 2020 Aug 6;12(8):e9588. doi: 10.7759/cureus.9588.

本文引用的文献

1
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.达雷妥尤单抗联合来那度胺和地塞米松治疗初治多发性骨髓瘤。
N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249.
2
Daratumumab for the Treatment of Multiple Myeloma.达雷妥尤单抗治疗多发性骨髓瘤。
Front Immunol. 2018 Jun 4;9:1228. doi: 10.3389/fimmu.2018.01228. eCollection 2018.
3
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.达雷妥尤单抗联合硼替佐米、美法仑和泼尼松治疗未经治疗的多发性骨髓瘤。
N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12.
4
Plasma Cell Myeloma in Children and Young Adults: A Report of 4 Cases From a Single Institution and a Review of the Literature.
J Pediatr Hematol Oncol. 2017 Aug;39(6):452-457. doi: 10.1097/MPH.0000000000000907.
5
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.达雷妥尤单抗联合泊马度胺及地塞米松治疗复发和/或难治性多发性骨髓瘤
Blood. 2017 Aug 24;130(8):974-981. doi: 10.1182/blood-2017-05-785246. Epub 2017 Jun 21.
6
Establishment of an innovative staging system for extramedullary plasmacytoma.建立一种用于髓外浆细胞瘤的创新分期系统。
BMC Cancer. 2016 Oct 8;16(1):777. doi: 10.1186/s12885-016-2824-x.
7
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751.
8
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、硼替佐米和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038.
9
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.达雷妥尤单抗、来那度胺和地塞米松用于复发多发性骨髓瘤的1/2期研究。
Blood. 2016 Oct 6;128(14):1821-1828. doi: 10.1182/blood-2016-07-726729. Epub 2016 Aug 16.
10
Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.多发性骨髓瘤:2016年诊断、风险分层及管理的最新进展
Am J Hematol. 2016 Jul;91(7):719-34. doi: 10.1002/ajh.24402.